Table 3.

Results of meta-analysis of histologic subtypes of MMR deficient ovarian cancers

HNPCC-associated ovarian cancers
MSI-H ovarian cancers
Ovarian cancers with loss of MMR expression
Pooled analysis of all 3 categories
Proportion (95% CI)Proportion (95% CI)Proportion (95% CI)Proportion (95% CI)
Serous0.42 (0.29-0.55)0.36 (0.18-0.57)0 (0)0.32 (0.20-0.44)
Nonserous0.57 (0.44-0.70)0.063 (0.42-0.81)0.95 (0.81-0.99)0.68 (0.56-0.80)
    Mucinous0.16 (0.08-0.25)0.22 (0.07-0.42)0.26 (0.05-0.55)0.19 (0.12-0.27)
    Endometrioid0.25 (0.17-0.35)0.32 (0.21-0.45)0.34 (0.10-0.64)0.29 (0.22-0.36)
    Clear cell0.17 (0.07-0.30)0.10 (0.009-0.27)0.35 (0.15-0.58)0.18 (0.09-0.28)
    Undifferentiated1 study1 study
    Mixed1 study1 study1 study0.24 (0.07-0.47)
  • NOTE: The table includes MMR-deficient ovarian cancers identified based on (a) positive family history and/or germline mutation analysis, (b) MSI-H status and/or (c) lack of MMR protein expression, stratified by each category, as well as the pooled analysis.